Navigation Links
Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
Date:8/28/2013

lists.

Dr. Brad Vince stated, "The endoscopy suite and additional medical expertise significantly broaden the clinical research capabilities we are able to offer our clients. This investment will be key for clients seeking to obtain safety and efficacy data in patients and healthy normal volunteers during the early development phase to more quickly reach sound drug development decisions."

About Vince & Associates Clinical Research

Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for more than a decade. Proud to be recognized in the industry as a "Center of Research Excellence", Vince & Associates has become a premier clinical research site by utilizing The Physician Research Model® of operation where study teams are led by highly experienced principal investigators intimately involved in all aspects of the clinical trial process.

Vince & Associates operates a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials, from the safety and security of the controlled access unit to the added features of a movie theater and game rooms.

About Altasciences

Altasciences is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithme Pharma (Quebec, Canada). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

Read the full story at http://www.prweb.com/releases/bra
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Bradley Vince of Vince & Associates in Kansas City Featured in Prominent Clinical Research Magazine
2. Clinical Immunology Society Appoints Vincent Bonagura, MD as Editor-in-Chief of the Journal of Clinical Immunology
3. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
4. Preliminary Research, Led By Dr. Vincent Giampapa, Finds Aged Adult Stem Cells Can Be Functionally Reprogrammed To Act Like Younger Cells
5. St. Vincent, Austen BioInnovation Institute Announce Strategic Partnership to Develop New Products
6. China Green Agriculture Inc. Presented at Farmer Dailys Branded Fertilizer Roadshow in Shaanxi Province
7. HemoShear Hires Industry Business Development Veteran Vincent Aurentz as Chief Business Officer
8. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
11. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... N.J. , March 3, 2015  Regenicin, Inc. ... company specializing in the development of and commercialization of ... tissues and organs, announced today that it has received ... with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... the Agreement, Amarantus made the final payments due to ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
(Date:3/3/2015)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... pets, announced today that it will release its fourth quarter ... the market close. The Company will host a conference call ... Interested parties may access the call by dialing toll-free (855) ... conference ID 98449349.  The call will also ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Personalized Medicine - ... , The aim of personalized ... right drug to the right patient and, in ... for a patient according to his/her genotype. This ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3
... condition of esophagus eliminated in 90 percent ... ... BARRX Medical, Inc., the,global technology leader for treating precancerous conditions of ... a,multi-center U.S. study were free of the highest-risk of Barrett,s,esophagus after ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that ... Annual Global Healthcare Conference on,May 19, 2008 at 4:55 ... 2008 UBS,Global Generic and Specialty Pharmaceuticals Conference on Thursday, ... EDT). The presentations will,be web cast live and may ...
... Escalon Medical Corp.,(Nasdaq: ESMC ) today announced ... March 31, 2008., For the third quarter of ... $6,900,000 reported in the same period last fiscal,year. Product ... the,Company,s business units., Net revenue for the third ...
Cached Biology Technology:New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... It,s long been known that alcohol use in ... birth defects, but researchers who study fetal alcohol syndrome ... disorder, detecting it early, or effectively treating it, say ... the issue of Developmental Neuroscience , four first-year ...
... How do we begin to understand what early life was ... planet shifted from an oxygen-free and probably ice-covered realm to ... who decodes the early record of life on Earth has ... a significantly clearer picture of this dynamic environment. Alison Olcott ...
... , THE WOODLANDS, Texas , June 15 ... company focused on discovering breakthrough treatments for human disease, announced today ... clinical trial of LX4211 for patients with type 2 ... June 19 – 22, 2010 in San Diego, ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Delineating primary and secondary organic carbon in neoproterozoic glacial sediments 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 3Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 4Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 5
Auto/Zyme Reagent...
4',6-Diamidino-2-phenylindole dihydrochloride...
...
Normal Bovine Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin lev...
Biology Products: